Interaction Between Risperidone and Flecainide

Mechanism of Interaction

Flecainide is a class IC antiarrhythmic that blocks sodium channels, primarily affecting cardiac conduction by prolonging the QRS interval, according to the American Heart Association 1, 2
Risperidone can affect cardiac repolarization, potentially increasing the risk of arrhythmias when combined with flecainide, as noted by the European Society of Cardiology 3

Flecainide is listed as having significant interactions with multiple medications, including antipsychotics, in cardiac guidelines from the American College of Cardiology 1, 2
The risk is particularly concerning in patients with structural heart disease or coronary artery disease, as stated by the European Heart Journal 4
Patients with pre-existing conduction abnormalities are also at increased risk, according to the American Heart Association 1, 2
Electrolyte abnormalities, such as low potassium or magnesium levels, can increase the risk of arrhythmias, as reported by the Journal of the American College of Cardiology 5

Baseline ECG should be obtained prior to initiating either medication, as recommended by the American College of Cardiology 3
Regular ECG monitoring is recommended during treatment, with particular attention to QRS duration and QT interval, according to the American Heart Association 1, 3
Serum electrolyte levels should be monitored and maintained within normal ranges, as stated by the European Heart Journal 4

If concurrent use is necessary, the lowest effective doses of both medications should be used, and strict ECG monitoring should be implemented, as recommended by the American College of Cardiology 1, 3
Alternative options to consider include amiodarone for arrhythmia management in patients on risperidone, as noted by the European Heart Journal 4

Absolute contraindications for this combination include structural heart disease or reduced left ventricular function, as stated by the European Heart Journal 4
History of myocardial infarction, pre-existing QT prolongation, and severe renal or hepatic impairment are also absolute contraindications, according to the Journal of the American College of Cardiology 5 and the American College of Cardiology 6